發(fā)布時間：2018-08-26 16:41

【摘要】：目的:探討急性B淋巴細胞白血病(B-ALL)免疫表型表達特征及臨床意義。方法:采用流式細胞術(FMC)對初診的50例BCR-ABL融合基因陰性的急性B淋巴細胞白血病患者進行免疫分型。觀察急性B淋巴細胞白血病的免疫表型表達特征及臨床意義。結果:50例患者中,B細胞抗原中CD19+表達率為84.00%,陽性表達率最高。T細胞抗原CD5、CD7可跨系表達。伴髓系抗原中CD13+表達率最高,表達率為48.00%。50例患者入院確診后均進行誘導化療,第一次化療后完全緩解(CR1)率為76.00%,總有效率為86.00%。男性患者第一次化療后CR1率為77.27%,總有效率為95.45%,女性CR1率及總有效率分別為75.00%、78.57%,男女兩組CR1率、總有效率比較不具備統(tǒng)計學差別。依據年齡分為≥40歲和40歲兩組,第一次化療后≥40歲組CR1率為57.14%,總有效率71.42%,40歲組CR1率為89.65%,總有效率為96.55%,≥40歲組CR1率、總有效率均低于40歲組,比較具備統(tǒng)計學差別。依據貧血嚴重程度可以將所有患者分成輕度貧血組和中重度貧血組,首次化療后輕度貧血組CR1率為100%,總有效率100%,中重度貧血組CR1率為62.50%,總有效率為78.12%,兩組之間CR1率、總有效率分別比較,輕度貧血組都高于中重度貧血組,具備統(tǒng)計學差別。29例CD10+組患者首次化療后CR1率為86.20%,總有效率為96.55%,21例CD10-組CR1率為61.90%,總有效率71.42%,CD10-組完全緩解率、總有效率都低于CD10+組,具備統(tǒng)計學差異。26例CD20+組患者首次化療后CR1率為57.69%,總有效率為73.08%,24例CD20-組患者第一次化療后完全緩解率為95.83%,總有效率100%,CD20-組的CR1率、總有效率都高于CD20+組,具備統(tǒng)計學意義。24例CD13+組患者首次化療后CR1率為62.50%,總有效率為70.83%,26例CD13-組患者CR率為88.46%,總有效率100%,CD13+組完全緩解率、總有效率均低于CD13-組,統(tǒng)計學比較存在差異。11例CD33+組患者首次化療后CR1率為45.45%,總有效率為54.54%,37例CD33-組患者CR1率為86.48%,總有效率94.59%,CD33+組完全緩解率、總有效率均低于CD33-組,統(tǒng)計學比較有差異。25例CD34+組患者首次化療后CR1率為64.00%,總有效率為72.00%,20例CD34-組患者CR1率為95.00%,總有效率100%,CD34+組完全緩解率、總有效率均低于CD34-組,統(tǒng)計學比較有差異。15例CD96+組患者首次化療后CR1率為46.66%,總有效率為60.00%,16例CD96-組患者CR1率為87.50%,總有效率93.75%,CD96-組的CR1率、總有效率均高于CD96+組,具備統(tǒng)計學差別。29例My+B-ALL組患者中有首次化療后CR1率為65.51%,總有效率為75.86%,21例My-B-ALL組患者中首次化療后CR1率為90.47%,總有效率100%,My-B-ALL組CR1率、總有效率兩者都高于My+B-ALL組,統(tǒng)計學比較有差異。CD34/CD13抗原共表達組占總例數(shù)的20.00%,CD34/CD33共表達組占總例數(shù)的14.00%,CD34/CD96共表達組占總例數(shù)的18.00%。CD34/CD13抗原共表達組和非共表達組的CR1率分別是30.00%,86.20%,其總有效率分別是30.00%,100%。CD34/CD33抗原共表達組和非共表達組的CR1率分別是28.57%,77.27%,其總有效率分別是28.57%,90.90%。CD34/CD96抗原共表達組和非共表達組的CR1率分別是22.22%,86.36%,其總有效率分別是33.33%,95.45%。CD34/CD13抗原共表達組CR1率、總有效率均明顯低于CD34/CD13非共表達組,具備顯著統(tǒng)計學意義。CD34/CD33共表達組的CR1率、總有效率均低于CD34/CD33非共表達組,具備統(tǒng)計學意義。CD34/CD96共表達組的CR1率、總有效率均低于CD34/CD96非共表達組,具備統(tǒng)計學意義。結論:1.CD19是B-ALL的敏感性、特異性抗原;CD7、CD5可跨系表達于B-ALL;B-ALL伴髓系抗原中CD13陽性率最高。2.性別對B-ALL臨床療效無影響;年齡是影響B(tài)-ALL臨床療效的因素;初診時貧血嚴重程度是影響B(tài)-ALL臨床療效的因素。3.CD10+與B-ALL臨床療效呈正相關,免疫表型CD20+、CD13+、CD33+、CD34+、CD96+均與B-ALL臨床療效呈負相關。4.My+B-ALL臨床療效差;抗原CD34/CD13、CD34/CD33、CD34/CD96共表達與B-ALL臨床療效呈負相關。
[Abstract]:Objective: To investigate the immunophenotypic characteristics and clinical significance of acute B-lymphoblastic leukemia (B-ALL). Methods: Immunophenotyping of 50 newly diagnosed patients with BCR-ABL fusion gene negative acute B-lymphoblastic leukemia was performed by flow cytometry (FMC). Results: The expression rate of CD19+ in B cell antigen was 84.00% and the positive rate was the highest. T cell antigen CD5 and CD7 could be expressed across lines. The expression rate of CD13+ in myeloid antigen was the highest (48.00%). After the first chemotherapy, the CR1 rate was 77.27%, the total effective rate was 95.45%, the female CR1 rate and the total effective rate were 75.00% and 78.57%, respectively. According to the severity of anemia, all patients can be divided into mild anemia group and moderate and severe anemia group. After the first chemotherapy, the CR1 rate of mild anemia group is 100%, the total effective rate is 100%, and the CR1 rate of moderate and severe anemia group is 62.50%. The total effective rate was 96.55%. The CR1 rate was 61.90%. The total effective rate was 71.42%. The total effective rate of CD10-group was lower than that of CD10+group. The total effective rate was 73.08%. The total effective rate was 95.83%. The total effective rate was 100%. The total effective rate was higher in the CD20 group than that in the CD20 + group. The total effective rate was 62.50% in the CD13 + group. The total effective rate was 100%. The total effective rate of CD13 + group was lower than that of CD13 - group. The total effective rate was 45.45%. The total effective rate was 54.54%. The total effective rate was 86.48%. The total effective rate was 94.59%. The total effective rate of CD33 + group was lower than that of CD13 - group. The CR1 rate was 64.00%, the total effective rate was 72.00%, the CR1 rate was 95.00%, the total effective rate was 100%, the total effective rate was 100%, and the total effective rate was lower in the CD34 + group than in the CD34 - group. The CR1 rate in the CD96 + group was 46.6% after the first chemotherapy. The total effective rate was 60.00%. The total effective rate was 87.50% and 93.75% in 16 patients with CD96-group. The total effective rate of CD96-group was higher than that of CD96+group. The total effective rate was 65.51% and 75.86% in 29 patients with My+B-ALL after the first chemotherapy. The total effective rate was 90.47% and 1.47% in 21 patients with My-B-ALL after the first chemotherapy. The CR1 rate and total effective rate in my-B-ALL group and my-B-ALL group were higher than those in my+B-ALL group. The CR1 rate of CD34/CD13 antigen co-expression group accounted for 20.00%, CD34/CD33 co-expression group accounted for 14.00%, CD34/CD96 co-expression group accounted for 18.00% and CD34/CD96 co-expression group accounted for 30.00% and 86.20% respectively. The total effective rates were 30.00% and 100%, respectively. The CR1 rates of CD34/CD33 co-expression group and non-co-expression group were 28.57% and 77.27%, respectively. The total effective rates were 28.57% and 90.90% respectively. The CR1 rates of CD34/CD96 co-expression group and non-co-expression group were 22.22% and 86.36% respectively. The total effective rates were 33.33% and 95.45% respectively. The total effective rate of the CD34/CD33 co-expression group was lower than that of the CD34/CD13 non-co-expression group. The total effective rate of the CD34/CD33 co-expression group was lower than that of the CD34/CD33 non-co-expression group. The total effective rate of the CD34/CD96 co-expression group was lower than that of the CD34/CD96 non-co-expression group. CD7 and CD5 can be expressed in B-ALL; CD13 positive rate is the highest in B-ALL with myeloid antigen. 2. Gender has no effect on clinical efficacy of B-ALL; age is the factor affecting clinical efficacy of B-ALL; anemia severity is the factor affecting clinical efficacy of B-ALL at initial diagnosis. 3. CD10 + is positively correlated with clinical efficacy of B-ALL, and immunophenotype is the highest. CD20 +, CD13 +, CD33 +, CD34 +, CD96 + were negatively correlated with the clinical efficacy of B-ALL. 4. My + B-ALL had poor clinical efficacy; the co-expression of antigen CD34/CD13, CD34/CD33, CD34/CD96 was negatively correlated with the clinical efficacy of B-ALL.
【學位授予單位】：延安大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R733.71

【參考文獻】

相關期刊論文 前10條

1 丁利娟;黃河;;CD19-CAR-T細胞治療難治復發(fā)急性淋巴細胞白血病的研究進展[J];中國腫瘤生物治療雜志;2017年01期

2 沈偉;韋永瓊;于霞;羅德幸;劉成桂;;兒童急性淋巴細胞白血病MICM檢測結果分析[J];檢驗醫(yī)學與臨床;2016年19期

3 石連霞;;急性淋巴細胞白血病微小殘留病診斷研究進展[J];臨床檢驗雜志;2016年09期

4 張向臣;劉衛(wèi)華;張秀蓮;;CD20在成人急性B淋巴細胞白血病中的表達價值[J];中國衛(wèi)生標準管理;2016年05期

5 王艷;王軍;熊學艷;鄭曉敏;;CD34、CD38抗原在兒童急性白血病中的表達意義[J];南通大學學報(醫(yī)學版);2016年01期

6 馬平;田亮;劉煒;王小穩(wěn);;CD20陽性表達及與兒童急性B淋巴細胞白血病預后相關性研究[J];醫(yī)藥論壇雜志;2015年11期

7 王曉雪;王萍萍;梁穎;李艷;顏曉菁;;成人急性淋巴細胞白血病免疫表型的特點分析[J];中國醫(yī)科大學學報;2015年10期

8 周進;王婧;劉輝;鄭慧菲;馬玲;王攀峰;顏霜;傅t$t$;;B系急性淋巴細胞白血病中CD20表達及其對預后影響[J];中國實驗血液學雜志;2015年03期

9 王會芳;蘇顯都;于彩霞;王家坡;王國增;王麗麗;張碩;李麗霞;李健;;125例成人急性髓系白血病免疫表型特點分析[J];解放軍醫(yī)學院學報;2015年04期

10 王毅捷;孫和順;馬亞震;;CD96及P選擇素在急性白血病患者外周血中的表達及臨床意義[J];血栓與止血學;2015年01期

相關碩士學位論文 前1條

1 吳穎;急性白血病患者造血干細胞CD96分子表達的初步研究[D];華中科技大學;2011年

，

本文編號：2205521